Free Trial
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

Galera Therapeutics logo
$0.02 +0.00 (+0.47%)
As of 02:20 PM Eastern

About Galera Therapeutics Stock (NASDAQ:GRTX)

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.08
Volume
48,050 shs
Average Volume
88,898 shs
Market Capitalization
$1.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Galera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
3rd Percentile Overall Score

GRTX MarketRank™: 

Galera Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Galera Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galera Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galera Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.02% of the float of Galera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galera Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Galera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Galera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galera Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Galera Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Galera Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.90% of the stock of Galera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.77% of the stock of Galera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galera Therapeutics' insider trading history.
Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRTX Stock News Headlines

GRTX Galera Therapeutics, Inc. - Seeking Alpha
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Galera Therapeutics extends agreement deadline
See More Headlines

GRTX Stock Analysis - Frequently Asked Questions

Galera Therapeutics' stock was trading at $0.0458 at the start of the year. Since then, GRTX stock has decreased by 52.8% and is now trading at $0.0216.

Galera Therapeutics, Inc. (NASDAQ:GRTX) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.

Galera Therapeutics (GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Nextera Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

Last Earnings
11/10/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTX
CIK
1563577
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.08 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-99.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.74
Quick Ratio
9.74

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.41) per share
Price / Book
-0.01

Miscellaneous

Outstanding Shares
75,462,000
Free Float
47,375,000
Market Cap
$1.63 million
Optionable
Optionable
Beta
1.91
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:GRTX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners